Phillip Md Et Al Frost Buys 25,000 Shares of Cocrystal Pharma (NASDAQ:COCP) Stock

Cocrystal Pharma, Inc. (NASDAQ:COCP) Director Phillip Md Et Al Frost bought 25,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The stock was bought at an average cost of $0.97 per share, for a total transaction of $24,250.00. Following the completion of the acquisition, the director directly owned 1,728,551 shares of the company’s stock, valued at approximately $1,676,694.47. This represents a 1.47% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, December 26th, Phillip Md Et Al Frost purchased 40,000 shares of Cocrystal Pharma stock. The shares were bought at an average price of $0.97 per share, with a total value of $38,800.00.
• On Wednesday, November 26th, Phillip Md Et Al Frost purchased 4,000 shares of Cocrystal Pharma stock. The stock was purchased at an average price of $0.99 per share, for a total transaction of $3,960.00.
• On Tuesday, November 25th, Phillip Md Et Al Frost acquired 20,000 shares of Cocrystal Pharma stock. The shares were purchased at an average cost of $0.94 per share, for a total transaction of $18,800.00.

Cocrystal Pharma Stock Performance

Shares of Cocrystal Pharma stock opened at $0.95 on Wednesday. The company has a 50-day simple moving average of $1.03 and a two-hundred day simple moving average of $1.32. The stock has a market capitalization of $13.07 million, a PE ratio of -1.01 and a beta of 1.05. Cocrystal Pharma, Inc. has a 52-week low of $0.90 and a 52-week high of $2.67.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.03. As a group, equities research analysts forecast that Cocrystal Pharma, Inc. will post -1.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cocrystal Pharma in a report on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Cocrystal Pharma currently has a consensus rating of “Hold” and an average price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.